MedTrace Logo

Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days

NCT00686179 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2008-09-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects on cardiac repolarisation of supratherapeutic doses of AZD3480 compared to placebo in healthy male volunteers, subgrouped as extensive metabolisers and poor metabolisers according to CYP2D6 metabolic capacity, using moxifloxacin as positive control.

Conditions

  • Healthy

Interventions

DRUG

AZD3480

Capsule, oral, single dose, 6 days

DRUG

Moxifloxacin

Capsule(encapsulated), oral, single dose

DRUG

PLACEBO

Capsule, oral, single dose

Sponsors & Collaborators

Principal Investigators

  • Hans-Göran Hårdemark · Clinical Neuroscience TA AstraZeneca R&D Södertälje, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-08-31
Completion
2008-08-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00686179 on ClinicalTrials.gov